Human pregnane X receptor: a novel target for anticancer drug development

Area of Science:

• Pharmacology
• Molecular Biology
• Oncology

Background:

• Multidrug resistance (MDR) impedes anticancer drug efficacy by altering drug metabolism and transport.
• Nuclear receptors, like the human Pregnane X Receptor (hPXR), regulate drug-metabolizing enzymes (DMEs) and efflux transporters, contributing to MDR.
• hPXR is a key regulator of cytochrome P450 3A4 (CYP3A4) and multidrug resistance protein 1 (MDR1).

Purpose of the Study:

• To review the role of hPXR as a target for overcoming MDR in cancer therapy.
• To highlight the significance of understanding ligand structural features for hPXR activation.
• To discuss the implications of hPXR targeting for novel anticancer drug development and evaluation.

Main Methods:

• Literature review of studies on hPXR activation and its role in MDR.
• Analysis of in silico modeling, in vitro assays, and in vivo experiments identifying ligand structural features.
• Synthesis of current knowledge on hPXR as a therapeutic target.

Main Results:

• Anticancer drug-induced MDR is often mediated by hPXR activation.
• hPXR can be activated by a wide range of structurally diverse ligands.
• Research has identified key structural features of ligands that activate hPXR.

Conclusions:

• hPXR is a promising target for developing new anticancer drugs.
• Targeting hPXR can improve the preclinical and clinical evaluation of anticancer agents.
• Modulating hPXR activity offers a strategy to combat MDR in cancer treatment.